High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors

Lack of disease in long-term nonprogressors with human immunodeficiency virus type 1 (HIV-1) infection was strongly associated with very low copy numbers of HIV-1 DNA and RNA in peripheral blood mononuclear cells and plasma and the presence of high levels of anti-HIV-1 CD8+ memory cytotoxic T lymphocytes specific for Gag, Pol, and Env, compared with levels present in intermediate and advanced progressors. CD8+ memory cytotoxic T lymphocytes may have an important role in controlling HIV-1 replication and preventing disease in long-term nonprogressors.

[1]  L. Kingsley,et al.  Quantitation of human immunodeficiency virus type 1 DNA and RNA by a novel internally controlled PCR assay , 1995, Journal of clinical microbiology.

[2]  J. Mellors,et al.  Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.

[3]  J. Margolick,et al.  Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[4]  C. Rinaldo,et al.  Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men. , 1995, AIDS research and human retroviruses.

[5]  J. Margolick,et al.  Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. , 1995, The New England journal of medicine.

[6]  D. Ho,et al.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. , 1995, The New England journal of medicine.

[7]  E. Vicenzi,et al.  Regulation of HIV expression by viral genes and cytokines , 1994, Journal of leukocyte biology.

[8]  J. Levy,et al.  Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein , 1994, The Journal of experimental medicine.

[9]  R. Welsh,et al.  Specificity and editing by apoptosis of virus-induced cytotoxic T lymphocytes. , 1994, Current opinion in immunology.

[10]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[11]  D. Richman,et al.  The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.

[12]  H. Sheppard,et al.  Circulating HIV-1-infected cell burden from seroconversion to AIDS: importance of postseroconversion viral load on disease course. , 1994, Journal of acquired immune deficiency syndromes.

[13]  S. Chevret,et al.  Provirus copy number to predict disease progression in asymptomatic human immunodeficiency virus type 1 infection. , 1994, The Journal of infectious diseases.

[14]  D. Baltimore,et al.  Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4+ lymphocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Fauci,et al.  Multifactorial nature of human immunodeficiency virus disease: implications for therapy. , 1993, Science.

[16]  L. Kingsley,et al.  Enhanced expression of human immunodeficiency virus type 1 correlates with development of AIDS. , 1993, Virology.

[17]  T. Whiteside,et al.  Effects of adoptive immunotherapy with autologous CD8+ T lymphocytes on immunologic parameters: lymphocyte subsets and cytotoxic activity. , 1993, Clinical immunology and immunopathology.

[18]  H. Schuitemaker,et al.  Virulent HIV strains? , 1993, AIDS.

[19]  J. Sprent.  Lifespans of naive, memory and effector lymphocytes. , 1993, Current opinion in immunology.

[20]  J. Giorgi,et al.  Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. , 1993, Journal of immunology.

[21]  X. Jin,et al.  Quantitative analysis of the human immunodeficiency virus type 1 (HIV- 1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein- Barr virus in late disease , 1993, The Journal of experimental medicine.

[22]  K. Rosenthal,et al.  The influence of lymphocyte counts and disease progression on circulating and inducible anti‐HIV-1 cytotoxic T‐cell activity in HIV‐1-infected subjects , 1992, AIDS.

[23]  R. Weinstein,et al.  In-Vitro Resistance to Zidovudine and Alpha-interferon in HIV-1 Isolates from Patients: Correlations with Treatment Duration and Response , 1992, Annals of Internal Medicine.

[24]  R. Redfield,et al.  Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease , 1992, Journal of virology.

[25]  Charles R. M. Bangham,et al.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition , 1991, Nature.

[26]  R. Koup,et al.  Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities , 1991, The Journal of experimental medicine.

[27]  S. Buchbinder,et al.  Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: immunologic and virologic characteristics. , 1991, The Journal of infectious diseases.

[28]  B. Moss,et al.  CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Margolick,et al.  Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. , 1990, Clinical immunology and immunopathology.

[30]  A. Régnault,et al.  Detection of primary cytotoxic T lymphocytes specific for the envelope glycoprotein of HIV‐1 by deletion of the env amino‐terminal signal sequence , 1990, European journal of immunology.

[31]  B. Guy,et al.  Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins , 1989, Journal of virology.

[32]  D. Tyler,et al.  CELLULAR ANTI-GP120 CYTOLYTIC REACTIVITIES IN HIV-1 SEROPOSITIVE INDIVIDUALS , 1988, The Lancet.

[33]  N. Letvin,et al.  A novel epitope of the LFA-1 antigen which can distinguish killer effector and suppressor cells in human CD8 cells , 1987, Nature.

[34]  J. Phair,et al.  The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. , 1987, American journal of epidemiology.

[35]  B. Walker,et al.  HIV-specific cytotoxic T lymphocytes in seropositive individuals , 1987, Nature.

[36]  E. Podack,et al.  Cytolytic cell functions , 1997 .

[37]  Rolf M. Zinkernagel,et al.  Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells , 1993, Nature.

[38]  Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. , 1987, MMWR supplements.

[39]  R. Redfield,et al.  Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. , 1986, MMWR. Morbidity and mortality weekly report.

[40]  Fazekas de St Groth.  The evaluation of limiting dilution assays. , 1982, Journal of immunological methods.